Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Levothyroxine | hsa00040 | Pentose and glucuronate interconversions | 9.59E-03 | 2 | P15121, P14550 | AKR1B1, AKR1A1 | More | | Levothyroxine | hsa00440 | Phosphonate and phosphinate metabolism | 2.16E-02 | 1 | Q9Y6K0 | CEPT1 | More | | Levothyroxine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Levothyroxine | hsa00561 | Glycerolipid metabolism | 7.94E-03 | 3 | P15121, P14550, Q86XP1 | AKR1B1, AKR1A1, DGKH | More | | Levothyroxine | hsa00564 | Glycerophospholipid metabolism | 2.52E-02 | 3 | P48651, Q9Y6K0, Q86XP1 | PTDSS1, CEPT1, DGKH | More | | Levothyroxine | hsa00565 | Ether lipid metabolism | 4.27E-02 | 1 | Q9Y6K0 | CEPT1 | More | | Levothyroxine | hsa00740 | Riboflavin metabolism | 2.16E-02 | 1 | Q969G6 | RFK | More | | Levothyroxine | hsa00785 | Lipoic acid metabolism | 4.27E-02 | 1 | Q9Y234 | LIPT1 | More | | Levothyroxine | hsa00983 | Drug metabolism - other enzymes | 3.10E-02 | 2 | P20839, Q16772 | IMPDH1, GSTA3 | More | | Levothyroxine | hsa01100 | Metabolic pathways | 2.79E-02 | 14 | Q9Y234, Q16772, Q02153, P20839, O94777, Q9Y6K0, Q86XP1, Q9UHK6, Q86VZ5, P48651, Q969G6, P14927, Q06055, Q9NVH6 | LIPT1, GSTA3, GUCY1B3, IMPDH1, DPM2, CEPT1, DGKH, AMACR, SGMS1, PTDSS1, RFK, UQCRB, ATP5G2, TMLHE | More | | Levothyroxine | hsa01240 | Biosynthesis of cofactors | 1.75E-02 | 2 | Q969G6, Q9Y234 | RFK, LIPT1 | More | | Levothyroxine | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Levothyroxine | hsa03010 | Ribosome | 1.60E-02 | 9 | P30050, P40429, P62906, P62917, Q9H0U6, P36578, P05386, P62249, P23396 | RPL12, RPL13A, RPL10A, RPL8, MRPL18, RPL4, RPLP1, RPS16, RPS3 | More | | Levothyroxine | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Levothyroxine | hsa03030 | DNA replication | 1.48E-02 | 3 | P49005, P33993, P15927 | POLD2, MCM7, RPA2 | More | | Levothyroxine | hsa03420 | Nucleotide excision repair | 4.91E-02 | 2 | P07992, P54727 | ERCC1, RAD23B | More | | Levothyroxine | hsa04015 | Rap1 signaling pathway | 2.26E-02 | 3 | P25116, Q8TEU7, P08514 | F2R, RAPGEF6, ITGA2B | More | | Levothyroxine | hsa04020 | Calcium signaling pathway | 5.81E-04 | 7 | Q96DU7, Q13557, P21860, P05141, P12236, P26678, P63092 | ITPKC, CAMK2D, ERBB3, SLC25A5, SLC25A6, PLN, GNAS | More | | Levothyroxine | hsa04022 | cGMP-PKG signaling pathway | 2.71E-04 | 9 | P24844, P61586, P26678, Q99941, P18848, Q8WYR1, P05141, P12236, Q15746 | MYL9, RHOA, PLN, CREBL1, ATF4, PIK3R5, SLC25A5, SLC25A6, MYLK | More | | Levothyroxine | hsa04024 | cAMP signaling pathway | 1.40E-02 | 3 | P48058, P25116, P24844 | GRIA4, F2R, MYL9 | More | | Levothyroxine | hsa04151 | PI3K-Akt signaling pathway | 1.36E-02 | 9 | P21860, P27348, O14944, P07900, Q15831, P22105, Q99941, P18848, O95988 | ERBB3, YWHAQ, EREG, HSP90AA1, STK11, TNXB, CREBL1, ATF4, TCL1B | More | | Levothyroxine | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Levothyroxine | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.12E-02 | 5 | P63092, Q99941, P18848, P26678, Q13557 | GNAS, CREBL1, ATF4, PLN, CAMK2D | More | | Levothyroxine | hsa04270 | Vascular smooth muscle contraction | 4.65E-02 | 2 | Q15746, P24844 | MYLK, MYL9 | More | | Levothyroxine | hsa04330 | Notch signaling pathway | 4.91E-02 | 2 | P49768, P78504 | PSEN1, JAG1 | More | | Levothyroxine | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Levothyroxine | hsa04510 | Focal adhesion | 3.36E-02 | 3 | P08514, Q15746, P24844 | ITGA2B, MYLK, MYL9 | More | | Levothyroxine | hsa04512 | ECM-receptor interaction | 2.44E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Levothyroxine | hsa04514 | Cell adhesion molecules | 4.65E-02 | 2 | P16109, O00501 | SELP, CLDN5 | More | | Levothyroxine | hsa04520 | Adherens junction | 4.91E-02 | 2 | P07947, P19784 | YES1, CSNK2A2 | More | | Levothyroxine | hsa04530 | Tight junction | 7.42E-04 | 4 | Q8TEU7, O00501, Q14247, P24844 | RAPGEF6, CLDN5, CTTN, MYL9 | More | | Levothyroxine | hsa04610 | Complement and coagulation cascades | 2.94E-02 | 2 | P25116, P10909 | F2R, CLU | More | | Levothyroxine | hsa04611 | Platelet activation | 1.59E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Levothyroxine | hsa04622 | RIG-I-like receptor signaling pathway | 1.63E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | | Levothyroxine | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | | Levothyroxine | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Levothyroxine | hsa04724 | Glutamatergic synapse | 2.94E-02 | 2 | P48058, Q9NSB8 | GRIA4, HOMER2 | More | | Levothyroxine | hsa04810 | Regulation of actin cytoskeleton | 1.38E-03 | 4 | P24844, Q15746, P08514, P25116 | MYL9, MYLK, ITGA2B, F2R | More | | Levothyroxine | hsa04911 | Insulin secretion | 4.47E-03 | 4 | P63092, Q99941, P18848, Q13557 | GNAS, CREBL1, ATF4, CAMK2D | More | | Levothyroxine | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Levothyroxine | hsa04921 | Oxytocin signaling pathway | 6.37E-03 | 3 | Q15746, P24844, Q8WYR1 | MYLK, MYL9, PIK3R5 | More | | Levothyroxine | hsa04925 | Aldosterone synthesis and secretion | 1.68E-02 | 4 | Q99941, P18848, P63092, Q13557 | CREBL1, ATF4, GNAS, CAMK2D | More | | Levothyroxine | hsa04927 | Cortisol synthesis and secretion | 2.40E-02 | 3 | Q99941, P18848, P63092 | CREBL1, ATF4, GNAS | More | | Levothyroxine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.33E-02 | 4 | P63092, P61586, Q99941, P18848 | GNAS, RHOA, CREBL1, ATF4 | More | | Levothyroxine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Levothyroxine | hsa04934 | Cushing syndrome | 1.37E-03 | 5 | Q99941, P18848, P63092, O15169, Q13557 | CREBL1, ATF4, GNAS, AXIN1, CAMK2D | More | | Levothyroxine | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Levothyroxine | hsa05010 | Alzheimer disease | 1.36E-02 | 9 | Q92542, O15239, P05496, P18848, O15169, P05141, P12236, P43686, P62195 | NCSTN, NDUFA1, ATP5G1, ATF4, AXIN1, SLC25A5, SLC25A6, PSMC4, PSMC5 | More | | Levothyroxine | hsa05012 | Parkinson disease | 2.88E-03 | 9 | O15239, P05496, P05141, P12236, P63092, P18848, P43686, P62195, Q13557 | NDUFA1, ATP5G1, SLC25A5, SLC25A6, GNAS, ATF4, PSMC4, PSMC5, CAMK2D | More | | Levothyroxine | hsa05014 | Amyotrophic lateral sclerosis | 3.92E-02 | 8 | P20333, O15239, P05496, P18848, P43686, P62195, P51991, P35658 | TNFRSF1B, NDUFA1, ATP5G1, ATF4, PSMC4, PSMC5, HNRPA3, NUP214 | More | | Levothyroxine | hsa05020 | Prion disease | 1.15E-02 | 9 | P46531, O15239, P05496, P18848, P05141, P12236, P43686, P62195, Q99941 | NOTCH1, NDUFA1, ATP5G1, ATF4, SLC25A5, SLC25A6, PSMC4, PSMC5, CREBL1 | More | | Levothyroxine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.57E-02 | 10 | O15239, P05496, P18848, P05141, P12236, P20333, O15169, Q13557, P43686, P62195 | NDUFA1, ATP5G1, ATF4, SLC25A5, SLC25A6, TNFRSF1B, AXIN1, CAMK2D, PSMC4, PSMC5 | More | | Levothyroxine | hsa05030 | Cocaine addiction | 2.40E-02 | 3 | P63092, Q99941, P18848 | GNAS, CREBL1, ATF4 | More | | Levothyroxine | hsa05031 | Amphetamine addiction | 4.47E-03 | 4 | Q13557, P63092, Q99941, P18848 | CAMK2D, GNAS, CREBL1, ATF4 | More | | Levothyroxine | hsa05130 | Pathogenic Escherichia coli infection | 2.51E-02 | 3 | Q14247, O00501, P25116 | CTTN, CLDN5, F2R | More | | Levothyroxine | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | | Levothyroxine | hsa05144 | Malaria | 1.17E-02 | 3 | P68871, P05107, P10145 | HBB, ITGB2, IL8 | More | | Levothyroxine | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | Levothyroxine | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Levothyroxine | hsa05203 | Viral carcinogenesis | 7.09E-03 | 6 | Q99941, P18848, P27348, Q15283, P61586, P61978 | CREBL1, ATF4, YWHAQ, RASA2, RHOA, HNRPK | More | | Levothyroxine | hsa05206 | MicroRNAs in cancer | 1.54E-02 | 6 | P21860, P61978, P46531, P63279, P22105, P61586 | ERBB3, HNRPK, NOTCH1, UBE2I, TNXB, RHOA | More | | Levothyroxine | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Levothyroxine | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | | Levothyroxine | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | Levothyroxine | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Levothyroxine | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Levothyroxine | hsa05415 | Diabetic cardiomyopathy | 1.92E-02 | 6 | P05141, P12236, O15239, P05496, Q13557, P26678 | SLC25A5, SLC25A6, NDUFA1, ATP5G1, CAMK2D, PLN | More | | |